Oncotarget

Reviews:

MEF2 signaling and human diseases

Xiao Chen, Bing Gao, Murugavel Ponnusamy, Zhijuan Lin and Jia Liu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:112152-112165. https://doi.org/10.18632/oncotarget.22899

Metrics: PDF 666 views  |   HTML 1668 views  |   ?  


Abstract

Xiao Chen1,2,*, Bing Gao1,3,*, Murugavel Ponnusamy2, Zhijuan Lin2 and Jia Liu1,3

1School of Pharmacy, Qingdao University, Qingdao 266021, China

2Institute for Translational Medicine, Qingdao University, Qingdao 266021, China

3School of Basic Medicine, Qingdao University, Qingdao 266021, China

*These authors have contributed equally to this work

Correspondence to:

Jia Liu, email: dadaliujia@qdu.edu.cn

Keywords: MEF2; human diseases; signaling pathway; microRNAs

Received: February 17, 2017    Accepted: September 09, 2017    Published: December 04, 2017

ABSTRACT

The members of myocyte Enhancer Factor 2 (MEF2) protein family was previously believed to function in the development of heart and muscle. Recent reports indicate that they are also closely associated with development and progression of many human diseases. Although their role in cancer biology is well established, the molecular mechanisms underlying their action is yet largely unknown. MEF2 family is closely associated with various signaling pathways, including Ca2+ signaling, MAP kinase signaling, Wnt signaling, PI3K/Akt signaling, etc. microRNAs also contribute to regulate the activities of MEF2. In this review, we summarize the known molecular mechanism by which MEF2 family contribute to human diseases.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22899